Biotechnology company
Appears in 1 story
Acquired by Johnson & Johnson in December 2025
Johnson & Johnson's experimental prostate cancer drug shrank tumors in 75 percent of patients with measurable disease in a Phase 1 trial. The results, presented at ESMO on October 25, are the first clinical data for JNJ-6143 — a molecule J&J acquired with its December 2025 purchase of Halda Therapeutics.
Updated 2 hours ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
